Greenwich LifeSciences Inc Ordinary Shares GLSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GLSI is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $13.14
- Day Range
- $12.36–13.18
- 52-Week Range
- $7.58–21.44
- Bid/Ask
- $5.08 / $20.19
- Market Cap
- $162.53 Mil
- Volume/Avg
- 28,651 / 55,017
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual’s immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
Comparables
Valuation
|
Metric
|
GLSI
|
NUVL
|
MRSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 24.20 | 6.15 | 9.42 |
Price/Sales | — | — | 9.07 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GLSI
|
NUVL
|
MRSN
|
|---|---|---|---|
Quick Ratio | 30.76 | 22.62 | 3.29 |
Current Ratio | 30.76 | 22.83 | 3.36 |
Interest Coverage | — | — | −44.11 |
Quick Ratio
GLSI
NUVL
MRSN
Profitability
|
Metric
|
GLSI
|
NUVL
|
MRSN
|
|---|---|---|---|
Return on Assets (Normalized) | −53.62% | −19.79% | −49.57% |
Return on Equity (Normalized) | −54.82% | −20.76% | −211.52% |
Return on Invested Capital (Normalized) | −58.59% | −25.56% | −146.81% |
Return on Assets
GLSI
NUVL
MRSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nchsdhrf | Rhtvd | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hgpxmfm | Njxvmyw | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hggrrlgvf | Rsxhh | $99.5 Bil | |
MRNA
| Moderna Inc | Mknbqjrm | Cnqwc | $38.8 Bil | |
ARGX
| argenx SE ADR | Dwbdlhvgy | Qwkf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mtpnzrxns | Jjsz | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ttgvfsqp | Hwtpbn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rrlbnyfjy | Lxxwzjl | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Frmbjxsb | Vrkccp | $12.5 Bil | |
INCY
| Incyte Corp | Scrlmmsgh | Dzbhry | $11.6 Bil |